Forus, an AI-powered healthcare technology company formerly known as Tandem, has raised more than $160 million to expand a national network designed to help new medicines reach patients more reliably. The New York-based company said it is building infrastructure that connects physicians, pharmacies, payers, and biopharma organizations at a time when medical innovation is advancing faster than the systems built to deliver it. The funding comes from a group of major investors including Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC.
Addressing a Persistent Gap in Medicine
The company’s announcement centers on a long-standing problem in healthcare: scientific breakthroughs do not automatically translate into patient access. Developing a new drug can take more than a decade and cost billions of dollars, yet even approved therapies often fail to reach all eligible patients because of administrative, insurance, and fulfillment barriers. Forus argues that modern medicine needs a more dependable operating layer between the moment a doctor chooses a treatment and the moment a patient begins therapy.
How the Platform Works
Forus has built an AI-enabled platform embedded into clinical workflows, where it helps automate the steps that typically slow down treatment access. These include insurance prior authorization, financial assistance coordination, and routing prescriptions to the right fulfillment channels. The company says its system supports every drug, payer, and pharmacy in the United States, while remaining free for doctors and patients.
Growth Across the United States
According to Forus, its platform is now used by thousands of medical practices and health systems across all 50 states. The company said provider adoption has increased tenfold year over year for each of the past two years, with growth driven entirely by word of mouth. Forus also said it now supports patients in nearly 80 percent of U.S. residential ZIP codes, including people with complex conditions who may otherwise struggle to access appropriate treatment.
Support for Doctors, Patients, and Biopharma
Forus positions its network as a tool that benefits multiple parts of the healthcare system, not just individual prescribing offices. For doctors, the platform is intended to reduce administrative friction and create more confidence that prescribed therapies will actually reach patients. For life sciences companies, the company says its visibility into prescription bottlenecks, patient drop-off points, and treatment patterns can support better research design, more effective launches, and broader investment in difficult disease areas.
Investor Perspective and Market Relevance
Sahir Jaggi, Forus’ founder and chief executive, said the company is focused on building the missing layer that turns medical discovery into real-world treatment access. He noted that clinicians across the country are already using the platform and said the company sees an opportunity to significantly expand the treatment options available to both doctors and patients. Thrive Capital Partner Kareem Zaki added that patients too often miss appropriate therapies not because the treatments do not exist, but because the delivery system fails to make them accessible in practice.
The $160 million raise gives Forus significant backing as it attempts to modernize one of healthcare’s most difficult operational challenges. By connecting providers, pharmacies, insurers, and biopharma companies through a single AI-powered network, the company is aiming to reduce the delays and complexity that can prevent patients from starting needed therapies. Its next phase will test whether rapid provider adoption and investor confidence can translate into a broader shift in how advanced medicines move from scientific discovery to everyday patient care.